Stockscreener 앱 받기
3.79
4.53%
-0.18
전일 마감가:
$3.97
열려 있는:
$3.97
하루 거래량:
763.02K
Relative Volume:
0.45
시가총액:
$481.00M
수익:
$433.14M
순이익/손실:
$4.95M
주가수익비율:
106.16
EPS:
0.0357
순현금흐름:
$6.55M
1주 성능:
-9.98%
1개월 성능:
-26.69%
6개월 성능:
-15.12%
1년 성능:
+13.81%
1일 변동 폭
$3.775
$3.98
1주일 범위
$3.775
$4.275
52주 변동 폭
$2.6101
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
명칭
Organogenesis Holdings Inc
전화
781-575-0775
주소
85 DAN ROAD, CANTON, MA
ORGO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
3.79 | 503.84M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Lake Street | Buy |
| 2024-02-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-08-26 | 재개 | Credit Suisse | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
| 2019-04-17 | 개시 | Oppenheimer | Outperform |
| 2019-04-11 | 개시 | SunTrust | Buy |
모두보기
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
About Us - FinancialContent
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28% - simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - Your Wyoming Link
Hedge Fund Bets: Is Organogenesis Holdings Inc benefiting from innovation trendsDay Trade & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - FinancialContent
Published on: 2026-01-13 05:15:38 - baoquankhu1.vn
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth? - Sahm
Organogenesis drops as Medicare to pull skin substitute LCDs (update) - MSN
Is Organogenesis Holdings Inc. (2PQ) stock protected from inflationJuly 2025 Action & Free Technical Pattern Based Buy Signals - Улправда
Is Organogenesis Holdings Inc. stock a buy in volatile markets2025 Top Decliners & Growth Oriented Trade Recommendations - Улправда
What margin trends mean for Organogenesis Holdings Inc. stockIPO Watch & Pattern Based Trade Signal System - Улправда
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis ... - Bluefield Daily Telegraph
User - FinancialContent
Workboat Indexes | WorkBoatINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - FinancialContent
ORGOOrganogenesis Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Three rising investors just landed bigger roles at a healthcare PE firm - Stock Titan
Organogenesis (NASDAQ:ORGO) Trading Down 5% – Time to Sell? - Defense World
Organogenesis (NASDAQ:ORGO) Shares Down 5%Here's What Happened - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring 64% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com - Investing.com Australia
Organogenesis Holdings extends leases for Canton facilities through 2032 - Investing.com
Organogenesis Extends Long-Term Leases for Key Facilities - TipRanks
Organogenesis (NASDAQ:ORGO) Shares Gap DownTime to Sell? - MarketBeat
Organogenesis' (ORGO) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision - Investing.com Australia
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision By Investing.com - Investing.com South Africa
Organogenesis begins FDA rolling review for knee arthritis treatment - Investing.com India
Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis - Nasdaq
Organogenesis begins FDA rolling review for knee arthritis treatment By Investing.com - Investing.com Nigeria
Organogenesis starts rolling submission for ReNu allograft for knee arthritis - Seeking Alpha
Organogenesis stock rises after initiating FDA application for knee arthritis treatment By Investing.com - Investing.com South Africa
Organogenesis stock rises after initiating FDA application for knee arthritis treatment - Investing.com Nigeria
Organogenesis Announces Initiation of Biologics License Application for ReNu® - The Manila Times
Organogenesis Holdings Inc. Initiates Biologics License Application for ReNu® to Address Knee Osteoarthritis Pain - Quiver Quantitative
Biologic treatment for knee arthritis pain begins FDA license bid - Stock Titan
Gains Recap: Is Organogenesis Holdings Inc stock dividend yield sustainableWeekly Gains Report & Fast Gaining Stock Strategy Reports - moha.gov.vn
Net current asset value per share of Organogenesis Holdings, Inc. Class A – BER:2PQ - TradingView — Track All Markets
BTIG reiterates Organogenesis Holdings (ORGO) buy recommendation - MSN
Is Organogenesis Holdings Inc. stock a bargain at current levels2025 Momentum Check & Advanced Technical Analysis Signals - Улправда
Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO - MarketBeat
Organogenesis (NASDAQ:ORGO) Shares Down 3.7% on Insider Selling - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: 47% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is Organogenesis Holdings Inc. stock dividend yield sustainableJuly 2025 Outlook & Breakout Confirmation Trade Signals - DonanımHaber
Is Organogenesis Holdings Inc. stock supported by strong cash flows2025 Price Targets & Free Safe Capital Growth Stock Tips - Улправда
Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf Sells 200,000 Shares - MarketBeat
Organogenesis Holdings Inc (ORGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
1.45%
자본화:
|
볼륨(24시간):